• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
Home
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
    • Ophthalmology
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • CRO Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
Home
Trending
Hamburger Menu Hamburger Menu
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
    • Ophthalmology
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • CRO Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us

hepatitis

Signage for the Department of Health and Human Services HHS headquarters is seen on April 02 2025 in Washington DC
Favicon Fierce Healthcare

Judge sides with states, blocking HHS reorg and mass layoffs

States won a partial block of mass layoffs and the HHS reorganization imposed by the Trump administration in a ruling by a district judge Tuesday.
Noah Tong Jul 1, 2025 3:30pm
plan B fail reroute road path trail miss

Surrozen drops sole clinical-stage drug over weak hepatitis data

Mar 24, 2025 10:50am
FDA stop sign

FDA hits Kezar's zetomipzomib with 2nd clinical hold in 2 months

Nov 13, 2024 5:22am
cancer target detection radiopharma radio

Kezar drops solid tumor yet to prove its worth in phase 1 trial

Aug 14, 2024 5:09am
stock market down crash fail shares

Durect fails alcohol-associated hepatitis trial, plans phase 3

Nov 8, 2023 7:57am

Home
  • Connect
    • The Team
    • Advertise
    • Marketing Kit
    • Let's Talk
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Pharma
    • Fierce Biotech
    • Fierce Healthcare
  • Our Events
    • Life Sciences Events
©2025 Questex LLC All rights reserved.
Terms of use
Privacy Policy
Privacy Settings